Posted 4/25/2020 12:32 PM (GMT -8)
I was looking at the data on this website, https://covidibd.org/current-data/, and was surprised to see that Mesalamine / 5-ASA seems to put people at relatively high risk of hospitalization and death due to Covid. Nearly 50 percent of patients on mesalamine needed hospitalization, and 8 percent died. This was a surprising number to me, given that anything I've read about the risks of ibd and covid tend to highlight the fact that prednisone and the immune suppressing drugs put a person at risk, and mesalamine doesn't fall into this category.
But if you look on the ibd /covid site, the case summary clearly shows that after prednisone, mesalamine had the highest incidence of hospitalization and death out of all the ibd meds.
Does anyone have any thoughts on this? I realize it is a relatively small sample size, but I find these numbers concerning, especially considering that the general advice that's out there is that mesalamine is not a risk factor for increased covid complications.